Mochi Health vs NuviaRx
Two GLP-1 desks, one scoreboard. We put Mochi Health and NuviaRx head-to-head on the published Brief Score — the same six factors, scored the same way.
Mochi Health
The verdict
Mochi Health takes this head-to-head.
Mochi Health scores 81 to 72 on our six-factor Brief Score — A recognizable coaching-forward brand, but availability is capped at roughly 15 states.
That doesn't make NuviaRx a bad call — it's best for shoppers wanting low-cost, transparent compounded glp-1 with free delivery. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Mochi Health | NuviaRx | |
|---|---|---|
| Brief Score | 81/100 (B−) | 72/100 (C) |
| Semaglutide | $138/mo | From $140/mo (all doses, compounded) |
| Tirzepatide | $238/mo | From $170/mo (all doses, compounded) |
| Coverage | 15 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Mochi Health: $138 sema / $238 tirz; footprint capped near 15 states.
NuviaRx: New to the tracker on 1 August 2026. The published line reads From $140/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.